Biohaven Pharmaceutical Holding has established an expanded access program (EAP) with sublingual BHV-0223, an investigational drug candidate, for patients with amyotrophic lateral sclerosis (ALS). Through this program, physicians may be able to obtain BHV-0223 for their eligible patients with ALS at no cost. BHV-0223 is a sublingual and lower dose formulation of riluzole which employs the Zydis orally dissolving…